Pharmaceutical - Antibiotics and Infectious diseases, Pricing

Filter

Popular Filters

US infectious disease specialists’ prescribing choices for GNIs

US infectious disease specialists’ prescribing choices for GNIs

09-10-2013

A majority of US surveyed infectious disease specialists are willing to prescribe novel antibiotics if…

Antibiotics and Infectious diseasesMarkets & MarketingNorth AmericaPharmaceuticalPricing

Bayer in settlement over Cipro pricing

04-09-2013

A partial settlement has been reached in a US class action law suit involving the prescription antibiotic…

Antibiotics and Infectious diseasesBayerCiproGenericsLegalNorth AmericaPharmaceuticalPricing

IQWiG finds added benefit for Dificlir in C. difficile infections

16-07-2013

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) has now assessed additional information…

Antibiotics and Infectious diseasesAstellas PharmaDificlirEuropePharmaceuticalPricingRegulation

UNITAID market power results in price cuts of up to 80% for HIV/AIDS, TB and malaria products

30-05-2013

UNITAID's approach to transform health product markets has delivered price reductions of up to 80% for…

Anti-viralsAntibiotics and Infectious diseasesGenericsGlobalHealthcarePharmaceuticalPricingTropical diseases

IQWiG finds no added proven benefit for Astellas' fidaxomicin in Clostridium difficile infection

23-04-2013

In an early benefit assessment under Germany's Act on the Reform of the Market for Medicinal Products…

Antibiotics and Infectious diseasesAstellas PharmaDificidDificlirfidaxomicinPharmaceuticalPricingRegulation

Preliminary NICE guidance negative on Pfizer's Xalkori for lung cancer; backs Colobreathe and Tobi Podhaler for CF

27-03-2013

Much to the disappointment of the company, this morning (March 27), UK drugs watchdog the National Institute…

Antibiotics and Infectious diseasesColoBreatheEuropeForest LaboratoriesNovartisOncologyPfizerPharmaceuticalPricingRare diseasesRegulationTobi PodhalerXalkori

NICE "green light" for Novartis' Tobi Podhaler and Forest's Colobreathe

24-01-2013

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in a final draft…

Antibiotics and Infectious diseasesColoBreatheEuropeForest LaboratoriesNovartisPharmaceuticalPricingRare diseasesRegulationTobi Podhaler

Company Spotlight

ImmunoGen

ImmunoGen

Back to top